Genotype and allele characteristics of FokI, BsmI, and TaqI VDR-polymorphisms and BsmI-TaqI haplotypes of 74 melanoma patients and comparisons between groups of 100% VDR-positive cells (n=12) vs. <100% (n=62); over the median (>20%) VDR-positive cells (n=36) versus below or equal the median (≤20%) (n=38); and absence of VDR-positive cell (n=15) versus remaining cases with detected VDR expression (n=59)
| VDR genotype or combined genotype | All melanoma patients (n=74) | 100% VDR-positive cells (n=12) | <100% VDR-positive cells (n=62) | OR (CI) 100% vs. <100% VDR-positive | P=100% vs.<100% VDR-positive | >20%a VDR-positive cells (n=36) | ≤20% VDR-positive cells (n=38) | OR (CI)>20% vs. ≤20% VDR-positive | P > 20% vs. ≤20% VDR-positive | VDR absence (0% positive) (n=15) | VDR presence (>0% positive) (n=59) | OR (CI) VDR absence vs. presence | PVDR absence vs. presence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FokI genotype | |||||||||||||
| FF | 32 (43.2) | 5 (41.7) | 27 (43.5) | 0.93 (0.26–3.24) | 0.904 | 16 (44.4) | 16 (42.1) | 1.10 (0.44–2.76) | 0.839 | 7 (46.7) | 25 (42.4) | 1.19 (0.38–3.71) | 0.764 |
| Ff | 33 (44.6) | 5 (41.7) | 28 (45.2) | 0.87 (0.25–3.03) | 0.824 | 14 (38.9) | 19 (50.0) | 0.64 (0.25–1.60) | 0.337 | 6 (40.0) | 27 (45.8) | 0.79 (0.25–2.50) | 0.688 |
| ff | 9 (12.2) | 2 (16.7) | 7 (11.3) | 1.57 (0.28–8.69) | 0.633 | 6 (16.7) | 3 (7.9) | 2.33 (0.54–10.1) | 0.302 | 2 (13.3) | 7 (11.9) | 1.14 (0.21–6.16) | 1.000 |
| F allele | 97/148 (65.5) | 15/24 (62.5) | 82/124 (66.1) | 0.85 (0.34–2.11) | 0.732 | 46/72 (63.9) | 51/76 (67.1) | 0.87 (0.44–1.71) | 0.681 | 20/30 (66.7) | 77/118 (65.3) | 1.06 (0.46–2.49) | 0.884 |
| f allele | 51/148 (34.5) | 9/24 (37.5) | 42/124 (33.9) | 1.17 (0.47–2.90 | 0.732 | 26/72 (36.1) | 25/76 (32.9) | 1.15 (0.58–2.27) | 0.681 | 10/30 (33.3) | 41/118 (34.7) | 0.94 (0.40–2.19) | 0.884 |
| BsmI genotype | |||||||||||||
| BB | 23 (31.1) | 5 (41.7) | 18 (29.0) | 1.75 (0.49–6.23) | 0.498 | 9 (25.0) | 14 (36.8) | 0.57 (0.21–1.56) | 0.271 | 6 (40.0) | 17 (28.8) | 1.65 (0.51–5.34) | 0.533 |
| Bb | 38 (51.4) | 4 (33.3) | 34 (54.8) | 0.41 (0.11–1.51) | 0.172 | 22 (61.1) | 16 (42.1) | 2.16 (0.85–5.47) | 0.102 | 6 (40.0) | 32 (54.2) | 0.56 (0.18–1.78) | 0.325 |
| Bb | 13 (17.6) | 3 (25.0) | 10 (16.1) | 1.73 (0.40–7.55) | 0.432 | 5 (13.9) | 8 (21.1) | 0.60 (0.18–2.06) | 0.418 | 3 (20.0) | 10 (16.9) | 1.22 (0.29–5.15) | 0.719 |
| B allele | 84/148 (56.8) | 14/24 (58.3) | 70/124 (56.5) | 1.08 (0.44–2.62) | 0.865 | 40/72 (55.6) | 44/76 (57.9) | 0.91 (0.47–1.74) | 0.774 | 18/30 (60.0) | 66/118 (55.9) | 1.18 (0.52–2.67) | 0.688 |
| b allele | 64/148 (43.2) | 10/24 (41.7) | 54/124 (43.5) | 0.93 (0.38–2.24) | 0.865 | 32/72 (44.4) | 32/76 (42.1) | 1.10 (0.57–2.11) | 0.774 | 12/30 (40.0) | 52/118 (44.1) | 0.85 (0.37–1.91) | 0.688 |
| TaqI genotype | |||||||||||||
| TT | 24 (32.4) | 3 (25.0) | 21 (33.9) | 0.65 (0.16–2.66) | 0.740 | 10 (27.8) | 14 (36.8) | 0.66 (0.25–1.76) | 0.405 | 6 (40.0) | 18 (30.5) | 1.52 (0.47–4.90) | 0.543 |
| Tt | 38 (51.4) | 7 (58.3) | 31 (50.0) | 1.40 (0.40–4.89) | 0.597 | 22 (61.1) | 16 (42.1) | 2.16 (0.85–5.47) | 0.102 | 8 (53.3) | 30 (50.8) | 1.10 (0.35–3.44) | 0.863 |
| tt | 12 (16.2) | 2 (16.7) | 10 (16.1) | 1.04 (0.20–5.48) | 1.000 | 4 (11.1) | 8 (21.1) | 0.47 (0.13–1.72) | 0.246 | 1 (6.7) | 11 (18.6) | 0.31 (0.04–2.63) | 0.439 |
| T allele | 86/148 (58.1) | 13/24 (54.2) | 73/124 (58.9) | 0.83 (0.34–1.99) | 0.669 | 42/72 (58.3) | 44/76 (57.9) | 1.02 (0.53–1.96) | 0.957 | 20/30 (66.7) | 66/118 (55.9) | 1.58 (0.68–3.66) | 0.287 |
| t allele | 62/148 (41.9) | 11/24 (45.8) | 51/124 (41.1) | 1.21 (0.50–2.92) | 0.669 | 30/72 (41.7) | 32/76 (42.1) | 0.98 (0.51–1.89) | 0.957 | 10/30 (33.3) | 52/118 (44.1) | 0.63 (0.27–1.47) | 0.287 |
| BsmI-TaqI combined genotype | |||||||||||||
| BBTT | 1 (1.4) | 0 (–) | 1 (1.6) | –b | 1.000 | 0 (–) | 1 (2.6) | –b | 1.000 | 1 (6.7) | 0 (–) | –b | 0.203 |
| BBTt | 10 (13.5) | 3 (25.0) | 7 (11.3) | 2.62 (0.57–12.0) | 0.351 | 5 (13.9) | 5 (13.2) | 1.06 (0.28–4.04) | 1.000 | 4 (26.7) | 6 (10.2) | 3.21 (0.77–13.3) | 0.110 |
| BBtt | 12 (16.2) | 2 (16.7) | 10 (16.1) | 1.04 (0.20–5.48) | 1.000 | 4 (11.1) | 8 (21.1) | 0.47 (0.13–1.72) | 0.246 | 1 (6.7) | 11 (18.6) | 0.31(0.04–2. 63) | 0.439 |
| BbTT | 10 (13.5) | 0 (–) | 10 (16.1) | –b | 0.200 | 5 (13.9) | 5 (13.2) | 1.06 (0.28–4.04) | 1.000 | 2 (13.3) | 8 (13.6) | 0.98 (0.19–5.18) | 1.000 |
| BbTt | 28 (37.8) | 4 (33.3) | 24 (38.7) | 0.79 (0.21–2.92) | 1.000 | 17 (47.2) | 11 (28.9) | 2.20 (0.84–5.73) | 0.105 | 4 (26.7) | 24 (40.7) | 0.53 (0.15–1.86) | 0.318 |
| bbTT | 13 (17.6) | 3 (25.0) | 10 (16.1) | 2.25 (0.50–10.1) | 0.432 | 5 (13.9) | 8 (21.1) | 0.60 (0.18–2.06) | 0.418 | 3 (20.0) | 10 (16.9) | 1.22 (0.29–5.15) | 0.719 |
aOver the median value of percentage (%) of cells positive for VDR protein. b OR uncountable because one or two of compared groups included zero subject.